1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
CMG Pharmaceutical Co., Ltd.

CMG Pharmaceutical Co., Ltd.

KKRX:058820
562.00
KRW
+9.00
(+1.63%)
-57.60EPS
257.54BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
252.37
253.58
274.04
335.78
354.86
428.89
482.3
464.1
504.8
635.32
669.17
698.74
730.96
756.67
Basic EPS, GAAP
3.66
1.76
-36.99
8.38
24.22
52.17
25.1
1.55
23
-3
46
19
-70
-57.6
Free Cash Flow per Basic Share
-159.9
-141.65
-12.41
1.98
4.6
-22.74
-72.62
-48.28
12.19
-41.51
-80.78
-221.8
-305.87
-368.93
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
498.13
498.19
466.86
813.18
837.92
889.57
1,297.11
1,304.11
1,329.83
1,331.63
1,369.64
1,364.67
1,363.31
1,364.41
Tangible Book Value per Share
433.51
393.51
349.5
750.33
772.94
820.52
1,217.37
1,217.29
1,238.34
1,228.05
1,228.7
1,209.49
1,238.37
1,239.01
Basic Weighted Avg Shares
81
90
99
98
117
116
122
139
138
129
140
142
144
146
Sales/Revenue/Turnover
20,402
22,753
27,042
32,970
41,536
49,865
58,623
64,460
69,475
82,197
93,907
99,100
105,229
110,119
Operating Margin (%)
3.88
1.94
-9.51
2.23
3.77
5.15
4.44
2.83
2.39
3.63
3.23
0.27
-3.51
-4.8
Depreciation Expense
1,116
1,465
1,890
2,085
1,855
1,846
2,106
2,436
2,491
2,284
2,558
3,346
3,082
2,907
Net Income, GAAP
296
158
-3,650
823
2,835
6,065
3,051
215
3,165
-388
6,455
2,695
-10,077
-8,383
Effective Tax Rate (%)
- -
- -
- -
- -
1.23
- -
20.47
62.2
10.81
- -
4.1
6.44
- -
- -
Profit Margin (%)
1.45
0.69
-13.5
2.5
6.83
12.16
5.2
0.33
4.56
-0.47
6.87
2.72
-9.58
-7.61
Working Capital
32,710
19,582
17,422
69,635
70,343
72,875
141,278
132,332
111,753
113,167
91,208
60,214
-8,477
18,570
LT Debt
1,415
- -
- -
- -
- -
- -
157
69
98
6,356
25,033
35,676
145
41,610
Total Equity
48,997
49,003
46,807
94,895
97,944
103,982
180,158
181,131
184,702
184,953
190,233
189,542
201,555
201,717
Return on Invested Capital (%)
1.69
0.93
- -
- -
1.63
- -
1.47
0.38
0.81
- -
1.43
0.39
- -
- -
Return on Capital (%)
2.88
0.56
- -
- -
2.94
- -
2.15
0.12
1.74
- -
3.2
2.08
- -
- -
Return on Common Equity (%)
0.74
0.32
-7.62
1.16
2.94
6.01
2.15
0.12
1.73
-0.21
3.44
1.42
-5.15
-4.3

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
70,562
71,863
46,686
LT Borrowings
- -
- -
41,500
LT Finance Leases
179
145
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
148
148
148
Market Capitalization
271,143
274,691
257,541

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
107,490
95,179
93,909
Cash, Cash Equivalents & STI
39,930
26,502
26,579
Accounts Receivable, Net
30,480
34,715
34,644
Inventories
32,053
29,542
28,123
Total Current Liabilities
99,919
103,656
75,340
Payables & Accruals
- -
- -
- -
ST Debt
70,562
71,863
46,686
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.68%
2.19%
6.34%
Free Cash Flow
-53.58%
-43.31%
39.98%
Net Income, GAAP
-94.22%
-207.06%
-473.96%
Sales/Revenue/Turnover
14.75%
10.41%
6.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,814
24,854
24,714
26,718
99,100
2025
20,625
22,669
30,402
31,534
105,229
2026
25,515
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
43
-19
-20.5
19
2025
-11
-76.4
38.84
-22.54
-70
2026
0.78
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ju-Hyeong Lee
Full Time Employees
206
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cheongdam-dong 18-20, #B01 Seoul SL South Korea 135-949
IPO Date
May 3, 2010
Website
cmgpharma.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
CMG Pharmaceutical Co., Ltd. (058820.KQ) develops, manufactures and sells oral thin film (OTF) pharmaceuticals and generic drugs in South Korea. The company offers Tadalafil OTF for erectile dysfunction; Entecavir OTF for hepatitis B; Aripiprazole OTF for schizophrenia; Montelukast OTF for asthma and allergic rhinitis; as well as antibiotics, antifungals, antivirals, anti-tuberculosis drugs, peptic ulcer treatments, dementia remedies and antihistamines. It pursues research in improved drugs including new formulations, combination drugs and extended-release products; generic drugs for cardiovascular diseases and anti-inflammatory pain relievers; synthetic new drugs targeting solid tumors, ovarian, colorectal and lung cancers; and overseas expansion with U.S. FDA IND approval for aripiprazole OTF plus bioequivalence approvals for tadalafil and entecavir OTF. Founded in 2001 and headquartered in Seoul, South Korea, the company maintains a strategic collaboration agreement with Handok Inc. for cancer treatments and operates as an affiliate of CHA Health Systems. Formerly Skynewpharm Co., Ltd., it changed its name in April 2013.